HIGHLIGHTS
SUMMARY
In a recent study, DPP-4 inhibitors are suggested for hospitalized COVID-19 patients suffering from diabetes, but the use of sulfonylureas and metformin against SARS-CoV-2-infected diabetic patients is still controversial. Even though earlier studies have demonstrated the use of anti-diabetics drugs for COVID-19 patients due to their minimal risk even after long exposure time, relatively low cost, and easy availability, further studies are warranted to confidently recommend these drugs for treating diabetic individuals infected with SARS-CoV-2. Enhanced Fatality in Diabetic Subjects Infected with SARS-CoV-2 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.